Farmacovigilanza SIF | Amlodipina (aggiornato al 22/1/2020)

A cura di Alessandra Russo. Specialista in Tossicologia Medica. Messina

Principio attivo	Effetto
Claritromicina (1)	Possibile aumento dell’esposizione ad amlodipina
Clopidogrel (2,3)	Possibile riduzione dell’effetto antiaggregante piastrinico e possibile aumento del rischio di eventi trombotici
Rifampicina (4)	Possibile riduzione dell’efficacia della amlodipina
Rifapentina (5)	Possibile riduzione dell’efficacia della amlodipina
Ritonavir (6)	Possibile aumento dell’esposizione ad amlodipina
Simvastatina (7,8)	Possibile aumento dell’esposizione alla simvastatina e possibile aumento del rischio di miopatia, inclusa rabdomiolisi

Bibliografia

Gandhi S, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 2013; 310: 2544-2553.
Lee SP, et al. Inhibitory interaction between calcium channel blocker and clopidogrel. – Efficacy of cilostazol to overcome it – . Circ J 2011; 75: 2581-2589.
Siller-Matula JM, et al. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008; 52: 1557-1563.
Agrawal A, et al. Rifampicin and anti-hypertensive drugs in chronic kidney disease: pharmacokinetic interactions and their clinical impact. Indian J Nephrol 2016; 26: 322-328.
Product Information: PRIFTIN(R) oral tablets, rifapentine oral tablets. sanofi-aventis US (per manufacturer), Bridgewater, NJ, Jun, 2018.
Product Information: VIEKIRA XR oral extended-release tablets, dasabuvir, ombitasvir, paritaprevir, ritonavir oral extended-release tablets. AbbVie Inc (per manufacturer), North Chicago, IL, Jul, 2018.
Product Information: AZOR(R) oral tablets, amlodipine olmesartan medoxomil oral tablets. Daiichi Sankyo, Inc. (per FDA), Parsippany, NJ, Jan, 2017.
Product Information: ZOCOR(R) oral tablets, simvastatin oral tablets. Merck Sharp & Dohme Corp. (per manufacturer), Whitehouse Station, NJ, Jun, 2011.

Link